Drug Approval | August 19, 2022
Tavneos recommended by England’s NICE for the treatment of AAV
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
First launches expected in H1 2022
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Subscribe To Our Newsletter & Stay Updated
